NCT07059676 (LIBINI-1) is a clinical trial of Zejula (Niraparib) in Advanced Ovarian Cancer, sponsored by Clinica Universidad de Navarra, Universidad de Navarra.

Who is sponsoring NCT07059676?

NCT07059676 is sponsored by Clinica Universidad de Navarra, Universidad de Navarra.

What drugs are being tested in NCT07059676?

Interventions in NCT07059676: Zejula (Niraparib).

What condition does NCT07059676 study?

NCT07059676 studies Advanced Ovarian Cancer.

Is NCT07059676 still recruiting?

NCT07059676 is currently not yet recruiting. Last updated 11 July 2025.

Last reviewed 2025-07-11 · How we verify

NCT07059676: LIBINI-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer

Not yet recruiting Last updated 11 July 2025

What this trial tests

trial testing Zejula (Niraparib) in Advanced Ovarian Cancer in 120 participants. Not yet recruiting.

Timeline

25 July 2025

Primary endpoint
31 December 2027

31 March 2028

Quick facts

Lead sponsor	Clinica Universidad de Navarra, Universidad de Navarra
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	120
Start date	25 July 2025
Primary completion	31 December 2027
Estimated completion	31 March 2028

Drugs / interventions tested

Zejula (Niraparib) — full drug profile →

Conditions studied

Advanced Ovarian Cancer — all drugs for Advanced Ovarian Cancer →

Sponsor

Clinica Universidad de Navarra, Universidad de Navarra

Who can join

18 and older, female only, with Advanced Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PARPi inhibitors have been incorporated into managing first-line advanced ovarian cancer with different approvals depending on homologous recombination (HR) status. Niraparib has received approval independent from HR status. Although the benefit is more remarkable in HR-deficient patients, there is no biomarker to predict sustained response to niraparib at the start of treatment helping the clinician to make decisions among the different treatment options. The aim of the LIBINI-1 (Liquid biopsy for predicting niraparib benefit if 1st line) study is to identify predictive biomarkers of sustained response to niraparib using liquid biopsy with two different technologies: 1. Proteomic and secretome analysis tools. The first part of the LIBINI-1 project is to create a platform for rapid screening and analysis by multiple detections of niraparib response-associated proteins in patients with advanced ovarian cancer. 2. ctDNA analysis. The second part of the LIBINI-1 project is to correlate the baseline level of ctDNA and change in ctDNA at 4 and 12 weeks with the benefit to niraparib.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Advanced Ovarian Cancer

Currently open trials in the same condition.

NCT06997029 — A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors · Phase 1 · recruiting
NCT06940921 — SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases · Phase 1, PHASE2 · active not recruiting
NCT04862325 — SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS · NA · active not recruiting
NCT04065009 — The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer · Phase 3 · active not recruiting
NCT03737643 — Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab a · Phase 3 · active not recruiting

Other Clinica Universidad de Navarra, Universidad de Navarra trials

Trials by the same sponsor.

NCT07370571 — NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE) · not yet recruiting
NCT07165431 — Effect of a Postbiotic Supplementation in Overweight and Obese Subjects: A Randomized Controlled Trial (PARABIOTICS-2). · NA · recruiting
NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
NCT07191210 — Co-Designed Comprehensive Transition Programme for First-Line Nurse Managers · NA · not yet recruiting
NCT07132060 — MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07059676 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Clinica Universidad de Navarra, Universidad de Navarra
Last refreshed: 11 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07059676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing